Highest-materiality recent filing
Synlogic confirms Nasdaq delisting, will trade on OTCQB as public shell
Withdrew Nasdaq hearing on Jan 16, 2026; shares suspended Jan 21, 2026.
Synlogic withdraws Nasdaq hearing; shares suspended Jan 21, will move to OTC Markets
Synlogic withdrew its Nasdaq hearing request on Jan 16, 2026, after being deemed a public shell.
Shareholders approve 2025 Equity Incentive Plan and reelect directors at annual meeting
2025 Plan approved: 1,000,000 new shares authorized, plus up to 332,468 from lapsing 2015 Plan awards.
Nasdaq notifies Synlogic it is a public shell; delisting possible unless hearing succeeds
Nasdaq Staff believes Synlogic is a public shell, citing zero revenue, minimal R&D costs, and reduced operations since Feb 2024.
Synlogic Director Michael Heffernan Resigns from Board and Committees
Michael Heffernan resigned from the Synlogic board and its audit and nominating/governance committees on February 20, 2025.
Synlogic board member Nick Leschly resigns effective Jan 10, 2025
Nick Leschly resigned from the Board and compensation committee on Jan 10, 2025.
Antoine Awad's employment ends Dec 31, 2024; receives $218,856 lump-sum (6 months salary) plus $246,213 retention bonus.
Synlogic stockholders reelect Nick Leschly as Class III director at annual meeting
Nick Leschly reelected as Class III director with 6,876,144 votes for and 317,492 withheld.
Synlogic posts Q3 net loss of $0.1M, cash $19.4M; evaluating strategic options
Net loss of $0.1M ($0.01 per share) vs $12.1M ($2.57 loss per share) in Q3 2023.
Synlogic reports Q2 net income $2M on restructuring gain; exploring strategic options
Cash and equivalents $20.0M as of June 30, 2024.
Synlogic posts Q1 net loss of $31.6M; retains advisor to explore strategic alternatives
Retained Lucid Capital Markets to evaluate acquisition, merger, or other strategic transaction.
Synlogic appoints James Flynn to board; three directors resign same week
James Flynn appointed as Class I director effective March 19; he manages Nerium Capital, a healthcare-focused investment fund.
Synlogic discontinues PKU program; Q4 net loss $14.5M, cash $47.7M
Discontinued Synpheny-3 pivotal study of SYNB1934 for PKU; evaluating strategic options.
On February 20, 2025, Michael Heffernan tendered his resignation as a member of the board of directors (the “Board”) of Synlogic, Inc. (the “Company”) and as a member of the audit committee and nominating and governance committee of the Board, effective immediately.
On January 10, 2025, Nick Leschly tendered his resignation as a member of the board of directors (the “Board”) of Synlogic, Inc. (the “Company”) and as a member of the compensation committee of the Board, effective immediately.
On March 20, 2024, Patricia N. Hurter, Ph.D. notified the Board of her decision to resi
On March 20, 2024, Mike Burgess, MB, CHB, Ph.D notified the Board of his decision to resign from the Board and the Audit Committee and the Science and Technology Committee, effective immediately.
On March 20, 2024, Lisa Kelly-Croswell notified the Board of her decision to resign from the Board and the Compensation Committee as well as the Nominating and Governance Committee, effective immediately.
appointed James Flynn effective March 19, 2024 (the “Effective Date”), as a director to the Board to serve as a Class I Director
Max materiality 0.85 · Median 0.75 · Most common event leadership